Mutaflor (Escherichia Coli Strain Nissle 1917)

Escherichia coli Nissle 1917, the active ingredient in Mutaflor, is a probiotic presented as a 2.5×10⁹ CFU per capsule for oral use. It modulates the intestinal microbiota and is employed to maintain remission in ulcerative colitis and other gastrointestinal disorders.

GNH USA supplies Mutaflor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution for this EU‑approved product. Ensuring timely delivery and regulatory compliance across regions.

Mutaflor acts on the gastrointestinal microbiota to support disease management in several conditions.

- Ulcerative colitis: helps maintain remission and reduce flare‑ups in patients with quiescent disease. - Inflammatory bowel disease: contributes to symptom control and mucosal health as an adjunct therapy. - Irritable bowel syndrome: may alleviate abdominal discomfort and irregular bowel patterns. - Infectious diarrhea recurrence: assists in preventing repeat episodes by restoring a balanced gut flora.

Adverse reactions to Mutaflor are generally uncommon but may occur.

Common Side Effects: - Bloating: mild abdominal distension reported by some users. - Flatulence: increased gas production during initial therapy. - Nausea: occasional feeling of queasiness. - Diarrhea: transient loose stools. - Constipation: occasional reduced bowel movements.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, or swelling indicating hypersensitivity. - Sepsis: systemic infection especially in severely immunocompromised patients. - Bacteremia: presence of the probiotic strain in the bloodstream, a rare event.

Before prescribing Mutaflor, consider the following precautions to ensure safe use.

- Immune status assessment: evaluate for severe immunodeficiency before initiation. - Antibiotic therapy: avoid concurrent broad‑spectrum antibiotics that may eradicate the probiotic. - Infection monitoring: watch for signs of systemic infection during treatment. - Pregnancy and lactation: use only if the potential benefit outweighs uncertain risk. - Store at ambient temperature below 25 °C: keep in the original container, protect from moisture and heat.

Mutaflor may interact with certain medicines; awareness of these interactions helps optimize therapy.

Major Interactions (Avoid): - Immunosuppressants: increased risk of opportunistic infection when combined. - Broad‑spectrum antibiotics: may eliminate the probiotic, reducing efficacy.

Moderate Interactions (Monitor Closely): - Antacids: altered gastric pH can affect bacterial survival. - Other probiotic products: potential competition for colonization sites. - Chemotherapy agents: possible additive effects on immune function.